Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CPN1 | P15169 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19703993 | 0.85 | NPC1 (0.47) | ALDH1A1LMNASMN1; SMN2NPC1 | |
| SCHEMBL19704302 | 0.81 | SMN1; SMN2 (0.38) | ALDH1A1LMNASMN1; SMN2NPC1KMT2A | |
| SCHEMBL19698367 | 0.81 | ALDH1A1 (0.44) | ALDH1A1LMNASMN1; SMN2EPHX2CACNA1H | |
| SCHEMBL22098001 | 0.80 | LMNA (0.62) | LMNASMN1; SMN2KMT2ADPP4GPR119 | |
| SCHEMBL20381496 | 0.79 | DPP4 (0.45) | ALDH1A1LMNAEPHX2NPC1KMT2A | |
| SCHEMBL20381508 | 0.79 | KMT2A (0.51) | ALDH1A1LMNASMN1; SMN2CACNA1HKMT2A | |
| SCHEMBL12125446 | 0.78 | CPN1 (0.41) | ALDH1A1EPHX2NPC1KMT2ACPN1 | |
| SCHEMBL19703989 | 0.78 | L3MBTL3 (0.44) | ALDH1A1LMNASMN1; SMN2CACNA1HNPC1 | |
| SCHEMBL18389803 | 0.77 | DPP4 (0.47) | ALDH1A1EPHX2NPC1CPN1CPB2 | |
| SCHEMBL12876398 | 0.76 | EPHX2 (0.50) | ALDH1A1EPHX2NPC1CPN1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | ALDH1A1 3212/4885LMNA 2400/4885SMN1; SMN2 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.